DK2041170T3 - Fremgangsmåde til fremstilling af insulinanaloger med dibasisk B-kædeende - Google Patents

Fremgangsmåde til fremstilling af insulinanaloger med dibasisk B-kædeende

Info

Publication number
DK2041170T3
DK2041170T3 DK07785903.1T DK07785903T DK2041170T3 DK 2041170 T3 DK2041170 T3 DK 2041170T3 DK 07785903 T DK07785903 T DK 07785903T DK 2041170 T3 DK2041170 T3 DK 2041170T3
Authority
DK
Denmark
Prior art keywords
dibasic
preparation
chain end
insulin analogs
end insulin
Prior art date
Application number
DK07785903.1T
Other languages
Danish (da)
English (en)
Inventor
Paul Habermann
Frank Zocher
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK2041170T3 publication Critical patent/DK2041170T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07785903.1T 2006-07-11 2007-07-05 Fremgangsmåde til fremstilling af insulinanaloger med dibasisk B-kædeende DK2041170T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006031955A DE102006031955A1 (de) 2006-07-11 2006-07-11 Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
PCT/EP2007/005933 WO2008006497A1 (de) 2006-07-11 2007-07-05 Verfahren zur herstellung von insulinanaloga mit dibasischem b-kettenende

Publications (1)

Publication Number Publication Date
DK2041170T3 true DK2041170T3 (da) 2013-08-05

Family

ID=38468893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07785903.1T DK2041170T3 (da) 2006-07-11 2007-07-05 Fremgangsmåde til fremstilling af insulinanaloger med dibasisk B-kædeende

Country Status (19)

Country Link
US (1) US8410048B2 (enExample)
EP (1) EP2041170B1 (enExample)
JP (1) JP5331685B2 (enExample)
KR (1) KR101439110B1 (enExample)
CN (1) CN101490082B (enExample)
AR (1) AR061865A1 (enExample)
AU (1) AU2007272057B2 (enExample)
BR (1) BRPI0714297A2 (enExample)
CA (1) CA2657041C (enExample)
DE (1) DE102006031955A1 (enExample)
DK (1) DK2041170T3 (enExample)
ES (1) ES2423684T3 (enExample)
IL (1) IL196360A (enExample)
MX (1) MX2009000275A (enExample)
MY (1) MY148984A (enExample)
NO (1) NO20090663L (enExample)
PT (1) PT2041170E (enExample)
TW (1) TWI440717B (enExample)
WO (1) WO2008006497A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
MY161892A (en) * 2008-02-19 2017-05-15 Biocon Ltd A method of obtaining a purified, biologically active heterologous protein
WO2012015692A2 (en) * 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2013015697A1 (en) 2011-07-28 2013-01-31 Mabion S.A. A recombinant protein, a polynucleotide encoding it as well as a method of obtaining insulin or its an analogue
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55138393A (en) * 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3636903A1 (de) 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
GB8618152D0 (en) * 1986-07-25 1986-09-03 Renishaw Plc Co-ordinate measuring
EP0294851A3 (de) * 1987-06-12 1990-05-09 Berlin-Chemie Ag Verfahren zur Herstellung von Humaninsulin und seinen Derivaten
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
DE4405179A1 (de) 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AR025646A1 (es) * 2000-09-13 2002-12-04 Beta Lab Sa Cepa de levaduras metilotroficas recombinantes productoras de un precursor de insulina, construcciones de adn y metodo para obtener la cepa.
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE10108100A1 (de) 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
IL161358A0 (en) * 2001-11-19 2004-09-27 Novo Nordisk As Process for preparing insulin compounds
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
EP1778839B1 (en) 2004-08-13 2008-07-09 Roche Diagniostics GMBH C-terminal modification of polypeptides
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen

Also Published As

Publication number Publication date
CN101490082A (zh) 2009-07-22
ES2423684T3 (es) 2013-09-23
AU2007272057B2 (en) 2012-06-14
AR061865A1 (es) 2008-09-24
WO2008006497A1 (de) 2008-01-17
PT2041170E (pt) 2013-07-18
DE102006031955A1 (de) 2008-01-17
NO20090663L (no) 2009-02-11
BRPI0714297A2 (pt) 2013-02-26
TWI440717B (zh) 2014-06-11
IL196360A (en) 2015-08-31
EP2041170B1 (de) 2013-05-01
US20090192073A1 (en) 2009-07-30
JP2009542235A (ja) 2009-12-03
EP2041170A1 (de) 2009-04-01
JP5331685B2 (ja) 2013-10-30
KR101439110B1 (ko) 2014-09-12
MY148984A (en) 2013-06-28
MX2009000275A (es) 2009-01-26
HK1130815A1 (en) 2010-01-08
CA2657041A1 (en) 2008-01-17
AU2007272057A1 (en) 2008-01-17
IL196360A0 (en) 2011-08-01
TW200817511A (en) 2008-04-16
CN101490082B (zh) 2013-08-14
KR20090038868A (ko) 2009-04-21
CA2657041C (en) 2016-04-26
US8410048B2 (en) 2013-04-02

Similar Documents

Publication Publication Date Title
DK2431359T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2489662T3 (da) Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
BRPI0823379A2 (pt) Análogos de glucagon
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
BRPI0823376A2 (pt) Análagos de glucagon
DK2118090T3 (da) Fremgangsmåde til fremstilling af et benzimidazolderivat
DK2231606T3 (da) Fremgangsmåder til fremstilling af cycloalkylcarboxamidopyridinbenzoesyrer
DK2248812T3 (da) Fused cyclic compounds as GPR40 receptor modulators
DK2242515T3 (da) Fremgangsmåde til fremstilling af en farmaceutisk kontrastmiddelformulering
DK2114886T3 (da) Fremgangsmåde til fremstilling af visse substituerede sulfiliminer
DK2358355T3 (da) Farmaceutisk sammensætning af en potent HCV-inhibitor til oral indgivelse
DK2007208T3 (da) Sterilisationsproces til fremstilling af en levnedsmiddelsammensætning
DK1884507T3 (da) Fremgangsmåde til fremstilling af glycerol
BRPI0906098A2 (pt) Método de preparação de um composto
EP2379493A4 (en) PROCESS FOR PRODUCING ASYMMETRIC BIS (THIOSEMICARBAZONE)
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK2080808T3 (da) Fremgangsmåde til fremstilling af l-aminosyre
DK3214083T3 (da) Fremgangsmåde til fremstilling af quinolonforbindelser
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK2307441T3 (da) Fremgangsmåde til fremstilling af insulinforbindelser
DK2041170T3 (da) Fremgangsmåde til fremstilling af insulinanaloger med dibasisk B-kædeende
DK2133420T3 (da) Fremgangsmåde til fremstilling af L-aminosyrer under anvendelse af forbedrede stammer af familien Enterobacteriaceae